Saik Urien

Summary

Country: France

Publications

  1. pmc Pharmacokinetics of epinephrine in patients with septic shock: modelization and interaction with endogenous neurohormonal status
    Imad Abboud
    Medical Intensive Care Unit, Hopital Europeen Georges Pompidou, Assistance Publique Hopitaux de Paris, Universite Paris Descartes, Paris, France
    Crit Care 13:R120. 2009
  2. doi Developmental pharmacokinetics of etoposide in 67 children: lack of dexamethasone effect
    Saik Urien
    CIC 0901 Inserm Necker Cochin and EA 3620, Paris, France
    Cancer Chemother Pharmacol 67:597-603. 2011
  3. pmc Lopinavir/ritonavir population pharmacokinetics in neonates and infants
    Saik Urien
    EA 3620, Universite Paris Descartes, Paris, France
    Br J Clin Pharmacol 71:956-60. 2011
  4. pmc Pregnancy-related effects on lamivudine pharmacokinetics in a population study with 228 women
    Sihem Benaboud
    Universite Paris Descartes, Paris, France
    Antimicrob Agents Chemother 56:776-82. 2012
  5. pmc Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children?
    Naïm Bouazza
    EA 3620, Universite Paris Descartes, Unite de recherche clinique, Hôpital Tarnier, 89 rue d Assas, 75006 Paris, France
    Antimicrob Agents Chemother 54:3280-6. 2010
  6. pmc Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women
    Sihem Benaboud
    Université Paris Descartes Sorbonne Paris Cité, EA3620, Paris, France
    Antimicrob Agents Chemother 56:857-62. 2012
  7. doi A novel pharmacokinetic approach to predict virologic failure in HIV-1-infected paediatric patients
    Naïm Bouazza
    Universite Paris Descartes, Sorbonne Paris, France
    AIDS 27:761-8. 2013
  8. pmc Evaluation of nevirapine dosing recommendations in HIV-infected children
    Frantz Foissac
    EA 3620 Université Paris Descartes Sorbonne Paris Cité, Unité de RechercheClinique, Hôpital Tarnier, 89 rue d Assas, Paris, France
    Br J Clin Pharmacol 76:137-44. 2013
  9. pmc Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents
    Frantz Foissac
    EA 3620 Université Paris Descartes, Paris, France
    Br J Clin Pharmacol 72:940-7. 2011
  10. doi Population pharmacokinetics of tenofovir in HIV-1-infected pediatric patients
    Naïm Bouazza
    EA 3620, Universite Paris Descartes, Sorbonne Paris Cité France, Paris, France
    J Acquir Immune Defic Syndr 58:283-8. 2011

Detail Information

Publications42

  1. pmc Pharmacokinetics of epinephrine in patients with septic shock: modelization and interaction with endogenous neurohormonal status
    Imad Abboud
    Medical Intensive Care Unit, Hopital Europeen Georges Pompidou, Assistance Publique Hopitaux de Paris, Universite Paris Descartes, Paris, France
    Crit Care 13:R120. 2009
    ..The purpose of this study was to investigate the pharmacokinetics of epinephrine and its determinants in patients with septic shock...
  2. doi Developmental pharmacokinetics of etoposide in 67 children: lack of dexamethasone effect
    Saik Urien
    CIC 0901 Inserm Necker Cochin and EA 3620, Paris, France
    Cancer Chemother Pharmacol 67:597-603. 2011
    ....
  3. pmc Lopinavir/ritonavir population pharmacokinetics in neonates and infants
    Saik Urien
    EA 3620, Universite Paris Descartes, Paris, France
    Br J Clin Pharmacol 71:956-60. 2011
    ..Lopinavir/ritonavir pharmacokinetics have been fully investigated in adults and children...
  4. pmc Pregnancy-related effects on lamivudine pharmacokinetics in a population study with 228 women
    Sihem Benaboud
    Universite Paris Descartes, Paris, France
    Antimicrob Agents Chemother 56:776-82. 2012
    ..9. Pregnant women had a 22% higher apparent clearance than nonpregnant and parturient women; however, this increase did not lead to subexposure and should not require a dosage adjustment...
  5. pmc Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children?
    Naïm Bouazza
    EA 3620, Universite Paris Descartes, Unite de recherche clinique, Hôpital Tarnier, 89 rue d Assas, 75006 Paris, France
    Antimicrob Agents Chemother 54:3280-6. 2010
    ..h was obtained with a 10-mg/kg once-daily lamivudine (3TC) dose for children below 17 kg; the recommended dose of 8 mg/kg seems to be sufficient in children weighing more than 17 kg. These assumptions should be prospectively confirmed...
  6. pmc Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women
    Sihem Benaboud
    Université Paris Descartes Sorbonne Paris Cité, EA3620, Paris, France
    Antimicrob Agents Chemother 56:857-62. 2012
    ....
  7. doi A novel pharmacokinetic approach to predict virologic failure in HIV-1-infected paediatric patients
    Naïm Bouazza
    Universite Paris Descartes, Sorbonne Paris, France
    AIDS 27:761-8. 2013
    ....
  8. pmc Evaluation of nevirapine dosing recommendations in HIV-infected children
    Frantz Foissac
    EA 3620 Université Paris Descartes Sorbonne Paris Cité, Unité de RechercheClinique, Hôpital Tarnier, 89 rue d Assas, Paris, France
    Br J Clin Pharmacol 76:137-44. 2013
    ..The aims of this study were to investigate the population pharmacokinetics of NVP in children, establish factors that influence NVP pharmacokinetics and evaluate the current dosing recommendations...
  9. pmc Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents
    Frantz Foissac
    EA 3620 Université Paris Descartes, Paris, France
    Br J Clin Pharmacol 72:940-7. 2011
    ..To investigate atazanavir (ATV) population pharmacokinetics in children and adolescents, establish factors that influence ATV pharmacokinetics and investigate the ATV exposure after recommended doses...
  10. doi Population pharmacokinetics of tenofovir in HIV-1-infected pediatric patients
    Naïm Bouazza
    EA 3620, Universite Paris Descartes, Sorbonne Paris Cité France, Paris, France
    J Acquir Immune Defic Syndr 58:283-8. 2011
    ..The main goal was then to suggest for the first time the dose of tenofovir disoproxil fumarate (TDF) to give in children...
  11. pmc Pharmacokinetic modelling of the placental transfer of nelfinavir and its M8 metabolite: a population study using 75 maternal-cord plasma samples
    Deborah Hirt
    Pharmacologie Clinique, Assistance Publique Hopitaux de Paris, Groupe Hospitalier Cochin Saint Vincent De Paul, Faculté de Médecine René Descartes, Universite Paris 5, Paris, France
    Br J Clin Pharmacol 64:634-44. 2007
    ..A population pharmacokinetic model was developed to characterize the transfer of nelfinavir and its active metabolite M8 from maternal to cord plasma and amniotic fluid...
  12. pmc Population pharmacokinetics study of recommended zidovudine doses in HIV-1-infected children
    Floris Fauchet
    EA 3620 Université Paris Descartes, Sorbonne Paris Cité, Paris, France
    Antimicrob Agents Chemother 57:4801-8. 2013
    ..9 kg and from 300 to 250 mg BID for the WB from 30 to 39.9 kg. The highest dose, 300 mg BID, should be started from body weights of 40 kg. ..
  13. doi High exposure to zidovudine during the first 2 weeks of life and concentration-toxicity relationships
    Deborah Hirt
    AP HP, Unite de recherche clinique, Hôpital Tarnier, Paris, France CIC 0901 Inserm, Cochin Necker, Paris, France AP HP, Service de Pharmacologie Clinique, Hopital Cochin, Universite Paris Descartes, Sorbonne Paris Cité, Paris, France INSERM CESP U1018 Equipe VIH et IST, Le Kremlin Bicetre, France University of Paris Sud, Le Kremlin Bicetre, France AP HP, Service d Epidémiologie et Santé Publique, Hopital Bicetre, Le Kremlin Bicetre, France AP HP, Service de Neonatologie, hôpital Cochin Port Royal, Paris, France Université Paris Descartes EA 3620, Sorbonne Paris Cité, Paris, France Laboratoire d Ethique Médicale, Universite Paris Descartes, Paris, France Service d Urgences Pédiatriques, Hopital Necker Enfants Malades, Assistance Publique Hopitaux de Paris, Paris, France and AP HP, Unite d immunologie, Hématologie et Rhumatologie pédiatriques
    J Acquir Immune Defic Syndr 63:555-62. 2013
    ....
  14. pmc Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children?
    Deborah Hirt
    EA3620, Universite Paris Descartes, Paris, France
    Antimicrob Agents Chemother 53:4407-13. 2009
    ..These assumptions should be prospectively confirmed...
  15. pmc Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates
    Sihem Benaboud
    EA3620, Universite Paris Descartes, Paris, France
    Antimicrob Agents Chemother 55:331-7. 2011
    ..The neonate must receive sdNVP immediately after birth when the infant is born less than 30 min after maternal drug intake to keep NVP concentrations above the IC(50)...
  16. doi Population pharmacokinetics of everolimus in cardiac recipients: comedications, ABCB1, and CYP3A5 polymorphisms
    Florian Lemaître
    Pharmacy Department, Pitie Salpetriere Hospital, Assistance Publique Hopitaux de Paris AP HP, Paris, France
    Ther Drug Monit 34:686-94. 2012
    ....
  17. pmc Pharmacokinetics and virological efficacy after switch to once-daily lopinavir-ritonavir in treatment-experienced HIV-1-infected children
    Frantz Foissac
    EA 3620 Université Paris Descartes, Paris, France
    Antimicrob Agents Chemother 55:4320-5. 2011
    ..The switch from the BID to the QD LPV/r regimen led to equivalent exposure and lower C(trough) values and resulted in lower levels of virological control in these antiretroviral-experienced children...
  18. pmc Developmental pharmacokinetics of lamivudine in 580 pediatric patients ranging from neonates to adolescents
    Naïm Bouazza
    EA 3620, Universite Paris Descartes, Paris, France
    Antimicrob Agents Chemother 55:3498-504. 2011
    ....
  19. pmc Population pharmacokinetics of emtricitabine in HIV-1-infected adult patients
    Elodie Valade
    EA 3620, Universite Paris Descartes, Sorbonne Paris Cité, Paris, France
    Antimicrob Agents Chemother 58:2256-61. 2014
    ..6 mg·h/liter). Administering 18 ml of emtricitabine oral solution (10 mg/ml) QD to patients with moderate renal impairment should yield emtricitabine exposures similar to those in patients with normal renal function...
  20. doi Determination of optimal cholecalciferol treatment in renal transplant recipients using a population pharmacokinetic approach
    Sihem Benaboud
    EA3620, Universite Paris Descartes, Sorbonne Paris Cité, Paris, France
    Eur J Clin Pharmacol 69:499-506. 2013
    ....
  21. ncbi Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis
    Deborah Hirt
    EA3620, Universite Paris Descartes, Paris, France
    Ther Drug Monit 31:557-65. 2009
    ..2 days. Serum Mn concentrations could be related to a decrease in PT; the effect was longer in patients with an early decrease in total bilirubin serum concentrations...
  22. pmc Population pharmacokinetics of clindamycin orally and intravenously administered in patients with osteomyelitis
    Naïm Bouazza
    EA 3620, Universite Paris Descartes, Sorbonne Paris Cité, Paris, France
    Br J Clin Pharmacol 74:971-7. 2012
    ....
  23. pmc Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates
    Deborah Hirt
    EA3620, Universite Paris Descartes, Paris, France
    Antimicrob Agents Chemother 53:1067-73. 2009
    ..FTC was shown to have good placental transfer (80%). Administering 1 mg FTC/kg as soon as possible after birth or 2 mg/kg 12 h after birth should produce neonatal concentrations comparable to the concentrations observed in adults...
  24. pmc Pregnancy-related effects on nelfinavir-M8 pharmacokinetics: a population study with 133 women
    Deborah Hirt
    Pharmacologie Clinique, Hopital Saint Vincent de Paul, Paris, France
    Antimicrob Agents Chemother 50:2079-86. 2006
    ..The Bayesian individual pharmacokinetic estimates suggested that the dosage should not be changed in pregnant women but may be doubled on the day of delivery...
  25. pmc Didanosine population pharmacokinetics in West African human immunodeficiency virus-infected children administered once-daily tablets in relation to efficacy after one year of treatment
    Deborah Hirt
    EA3620, Universite Paris Descartes, Paris, France
    Antimicrob Agents Chemother 53:4399-406. 2009
    ..03) than that with a lower AUC. A didanosine dose of 360 mg/m2 administered as tablets should be a more appropriate dose than 240 mg/m2 to improve efficacy for these children. However, data on adverse events with this dosage are missing...
  26. ncbi Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome
    Jean Sebastien Hulot
    Pharmacology Department, Institute of Cardiology, Pitie Salpetriere University Hospital, Paris, France
    Clin Pharmacol Ther 77:542-52. 2005
    ..However, little dosing information is available regarding the use of enoxaparin in patients with renal impairment...
  27. pmc Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 years
    Vincent Jullien
    Service de Pharmacologie Clinique, Groupe Hospitalier Cochin Saint Vincent De Paul, 74 82 Avenue Denfert Rochereau, 75674 Paris Cedex 14, France
    Antimicrob Agents Chemother 50:3548-55. 2006
    ..The consequences of these pharmacokinetic discrepancies and the necessity to modify the currently recommended dosage regimen should be further investigated...
  28. pmc Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy
    Vincent Jullien
    Service de Pharmacologie Clinique, Hopital Cochin Saint Vincent de Paul, 74 82 Avenue Denfert Rochereau, 75674 Paris Cedex 14, France
    Antimicrob Agents Chemother 49:3361-6. 2005
    ..In patients without tubular dysfunction, AUC(0-24) values markedly decreased from 6.7 to 1.4 mg . h/liter for BW/S(CR) increasing from 0.44 to 1.73. The relevance of a dosage adjustment based on BW/S(CR) should be further evaluated...
  29. pmc Vitamin D3 supplementation scheme in HIV-infected patients based upon pharmacokinetic modelling of 25-hydroxycholecalciferol
    Frantz Foissac
    EA 3620 Université Paris Descartes, Sorbonne Paris Cité, France
    Br J Clin Pharmacol 75:1312-20. 2013
    ....
  30. pmc Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients
    Naïm Bouazza
    EA 3620, Universite Paris Descartes, Sorbonne Paris Cité, France
    Orphanet J Rare Dis 6:86. 2011
    ..This study was aimed to describe the relationship between cysteamine plasma concentrations and white blood cell cystine levels, and to simulate an optimized administration scheme to improve the management of patients with cystinosis...
  31. ncbi Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy
    Demiana William Faltaos
    Pharmacology Department, Pitie Salpetriere University Hospital, Assistance Publique Hopitaux de Paris, Paris 6 University, Paris, France
    Cancer Chemother Pharmacol 58:626-33. 2006
    ..The final model was applied to the Bayesian estimation of MTX concentrations using two blood samples...
  32. ncbi Effect of renal function on the pharmacokinetics of enoxaparin and consequences on dose adjustment
    Jean Sebastien Hulot
    Pharmacology Department, Pitie Salpetriere University Hospital, Assistance Publique Hopitaux de Paris, Paris, France
    Ther Drug Monit 26:305-10. 2004
    ....
  33. ncbi Tubular transporters and clearance of adefovir
    Aude Servais
    Nephrology Department, Pitie Salpetriere University Hospital, 47 Boulevard de l Hopital, 75013, Paris, France
    Eur J Pharmacol 540:168-74. 2006
    ..Additional pharmacological inhibition of transporters decreased renal clearance, which may reflect inhibition of compensating transport mechanisms activated when MRP2 is lacking...
  34. pmc Population pharmacodynamic modeling and simulation of the respiratory effect of acetazolamide in decompensated COPD patients
    Nicholas Heming
    Service de Reanimation Medicale, Hopital Europeen Georges Pompidou, Universite Paris Descartes, Sorbonne Paris Cité, Assistance Publique Hopitaux de Paris, Paris, France
    PLoS ONE 9:e86313. 2014
    ..Chronic obstructive pulmonary disease (COPD) patients may develop metabolic alkalosis during weaning from mechanical ventilation. Acetazolamide is one of the treatments used to reverse metabolic alkalosis...
  35. pmc Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis
    Paola Sanchez-Pena
    Pharmacology Department, Pitie Salpetriere University Hospital, Assistance Publique Hospitaux de Paris, Paris 6 University, Paris, France
    Br J Clin Pharmacol 60:364-73. 2005
    ..v.) enoxaparin could be used as antithrombotic therapy in patients ongoing percutaneous coronary intervention (PCI). However, anti-Xa pharmacokinetics following different i.v. dosing regimens is not clearly established...
  36. pmc An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and pharmacodynamic study
    Deborah Hirt
    EA3620, Universite Paris Descartes, Paris, France
    Br J Clin Pharmacol 65:629-36. 2008
    ..Few studies of ibuprofen pharmacokinetics have been performed and were limited to small groups of preterm infants, showing a large intersubject variability and an increase in clearance with either postnatal or gestational age...
  37. pmc Population pharmacodynamic model of bicarbonate response to acetazolamide in mechanically ventilated chronic obstructive pulmonary disease patients
    Nicholas Heming
    Medical Intensive Care Unit, European Georges Pompidou Hospital AP HP, Universite Paris Descartes, Sorbonne Paris Cité, 20 rue Leblanc, 75908 Paris, France
    Crit Care 15:R213. 2011
    ..Little is known of the pharmacodynamics of acetazolamide in the critically ill. We undertook the pharmacodynamic modeling of bicarbonate response to acetazolamide in COPD patients under mechanical ventilation...
  38. doi Intravenous morphine titration in immediate postoperative pain management: population kinetic-pharmacodynamic and logistic regression analysis
    Hala Abou Hammoud
    Pharmacology Department, Pitie Salpetriere Hospital, Assistance Publique Hopitaux de Paris, Universite Pierre et Marie Curie Paris 6, Paris, France
    Pain 144:139-46. 2009
    ..Our study supported the possibility of modeling the time course of a complex response in the absence of pharmacokinetic data. The current data should lead to a more rational management of the immediate postoperative pain...
  39. ncbi Oxaliplatin plus irinotecan and FU-FOL combination and pharmacokinetic analysis in advanced colorectal cancer patients
    Marian A Gil-Delgado
    SOMPS, Salpetriere Hospital, Paris, France
    Am J Clin Oncol 27:294-8. 2004
    ..It would appear that the dose and schedule defined by this trial could be proposed as front-line therapy for advanced colorectal carcinoma to establish rapid disease control and to permit patients to proceed to surgery...
  40. doi Prediction tacrolimus blood levels based on the Bayesian method in adult kidney transplant patients
    Marie Antignac
    Pharmacy Department, Pitié Salpêtrière Hospital AP HP, 47 bd de l Hopital, 75013, Paris, France
    Eur J Drug Metab Pharmacokinet 36:25-33. 2011
    ..28 ± 0.58 ng/ml). The present study demonstrates the suitability of the Bayesian method for the prediction of trough blood concentrations of tacrolimus using only few samples in adult kidney transplantation recipients...
  41. ncbi Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance
    Marie Antignac
    Department of Pharmacy, Pitie Salpetriere Hospital, 47 bd de l Hopital, 75013, Paris, France
    Eur J Clin Pharmacol 61:409-16. 2005
    ..To investigate the population pharmacokinetics of tacrolimus in an adult liver transplant cohort using routine drug monitoring data and to identify patient characteristics that influence pharmacokinetic parameters...
  42. ncbi [Tubular transporters OAT1 and MRP2 and clearance of adefovir]
    Aude Servais
    Service de Nephrologie, CHU Pitie Salpetriere, Paris, France
    Nephrol Ther 1:296-300. 2005
    ..Additional pharmacological inhibition of transporters decreased renal clearance, which may reflect inhibition of compensating transport mechanisms activated when MRP2 is lacking...